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Single molecule binding of a ligand to a
G-protein-coupled receptor in real time using
fluorescence correlation spectroscopy, rendered
possible by nano-encapsulation in styrene maleic
acid lipid particles†
Rachael L. Grime, a,b Joelle Goulding, b,c Romez Uddin, d
Leigh A. Stoddart, b,c Stephen J. Hill, b,c David R. Poyner, d
Stephen J. Briddon b,c and Mark Wheatley *b,e
The fundamental importance of membrane proteins in cellular processes has driven a marked increase in
the use of membrane mimetic approaches for studying and exploiting these proteins. Nano-encapsula-
tion strategies which preserve the native lipid bilayer environment are particularly attractive. Consequently,
the use of poly(styrene co-maleic acid) (SMA) has been widely adopted to solubilise proteins directly from
cell membranes by spontaneously forming “SMA Lipid Particles” (SMALPs). G-protein-coupled receptors
(GPCRs) are ubiquitous “chemical switches”, are central to cell signalling throughout the evolutionary
tree, form the largest family of membrane proteins in humans and are a major drug discovery target.
GPCR-SMALPs that retain binding capability would be a versatile platform for a wide range of down-
stream applications. Here, using the adenosine A2A receptor (A2AR) as an archetypical GPCR, we show for
the first time the utility of fluorescence correlation spectroscopy (FCS) to characterise the binding capa-
bility of GPCRs following nano-encapsulation. Unbound fluorescent ligand CA200645 exhibited a mono-
phasic autocorrelation curve (dwell time, τD = 68 ± 2 μs; diffusion coefficient, D = 287 ± 15 μm2 s−1). In
the presence of A2AR-SMALP, bound ligand was also evident (τD = 625 ± 23 µs; D = 30 ± 4 μm2 s−1).
Using a non-receptor control (ZipA-SMALP) plus competition binding confirmed that this slower com-
ponent represented binding to the encapsulated A2AR. Consequently, the combination of GPCR-SMALP
and FCS is an effective platform for the quantitative real-time characterisation of nano-encapsulated
receptors, with single molecule sensitivity, that will have widespread utility for future exploitation of
GPCR-SMALPs in general.
Introduction
Membrane proteins have evolved to function within the
unique environment of the hydrated membrane bilayer, which
locates proteins in close association with lipids and provides
lateral pressure. Extracting membrane proteins from this
bilayer for purification and characterisation has, until recently,
universally required detergents. This detergent solubilisation
strips away closely-associated lipids, removes lateral pressure
and perturbs the protein conformation, resulting in protein
instability in the detergent micelle.1,2 This is particularly pro-
blematic for highly dynamic membrane proteins such as
G-protein-coupled receptors (GPCRs).3 GPCRs all share a
common protein architecture of a bundle of seven transmem-
brane helices and adopt a wide spectrum of conformational
states in executing their cell signalling role.4 They are found in
organisms throughout the phylogenetic tree including
humans, fish, insects, plants, slime-moulds and viruses (but
not bacteria) and form the largest class of ‘chemical switches’
in biology. They transduce signals from chemical messengers
acting on a cell, such as hormones and neurotransmitters,
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into biochemical changes within the cell via activation of intra-
cellular signalling cascades.5 As a result, they regulate almost
every physiological process. Consequently, GPCRs are the
largest class of membrane proteins in the human genome
(with >800 receptors). Furthermore, they are very important to
the pharmaceutical industry as they are the therapeutic target
of 30–40% of clinically-prescribed drugs.6,7
In recent years, a detergent-free method has been devel-
oped for solubilising membrane proteins using poly(styrene
co-maleic acid) (SMA). SMA spontaneously incorporates into
membranes to generate nanoscale sections of the lipid bilayer
as discs (∼10 nm in diameter) containing encapsulated mem-
brane protein, referred to as s̲tyrene m̲aleic a ̲cid l ̲ipid p ̲articles
(SMALPs).8–12 Nanoscale encapsulation of GPCRs in SMALPs
(GPCR-SMALPs) has potential utility for facilitating a wide
range of downstream approaches such as; supporting
biophysical10,11 and structural studies,13,14 a platform for dis-
covery of GPCR-targeted therapeutic antibodies using phage
display libraries, and for high-throughput screening in drug
discovery following immobilisation of GPCR-SMALPs on
surface plasmon resonance (SPR) chips.3 In addition, there is
potential for harnessing the exquisite ligand-recognition capa-
bility of GPCR-SMALPs into bespoke molecular detection
devices using synthetic biology. A pre-requisite to all of these
applications is establishing that the ligand-binding capability
of the encapsulated GPCR is preserved in the GPCR-SMALP.
It is noteworthy that in recent years there has been a rapid
increase in the design of fluorescent ligands for quantitative
characterisation of binding to GPCRs.15–17 This development
has enabled fluorescence correlation spectroscopy (FCS) to be
applied to studying GPCRs in cells.18 FCS is a quantitative
technique with single molecule sensitivity which uses confocal
optics and a high numerical aperture objective lens to generate
a small, defined illumination volume (∼0.25 fL). As a fluo-
rescent species moves through the detection volume, fluctu-
ations in fluorescent intensity are recorded in real time.
Statistical analysis of the time-dependency of these fluctu-
ations using autocorrelation analysis allows the average dwell
time of the fluorescent moiety within the detection volume to
be determined.18 Additionally, the amplitude of the autocorre-
lation curve is inversely proportional to the average concen-
tration of fluorescent particles in the detection volume. This
makes FCS particularly sensitive for investigating low concen-
trations of particles, a definite advantage for studying low-
abundance targets such as GPCRs. A property of FCS is that
the dwell time (τD) is proportional to the cube root of the mole-
cular mass, so a doubling of mass only increases τD by 1.3-
fold. When two fluorescent species are present in the detection
volume simultaneously, they can only be resolved by FCS if the
difference in their masses is large enough to yield a difference
in τD values of at least 1.6-fold.
19 Consequently, this combi-
nation of fluorescent probes and FCS has proven to be highly
effective for studying GPCRs embedded in the surface of live
cells.20–24 In this study we establish that nano-encapsulation of
a GPCR within a SMALP provides the required size differential
to make this a versatile strategy for quantitative analysis of
ligand : GPCR complex formation by FCS. In addition, it is likely
that the utility of FCS is not restricted to SMALPs but could
apply more widely to GPCRs embedded in nanoscale discs of
membrane irrespective of the method of encapsulation.
The adenosine A2A receptor (A2AR) is a typical GPCR with a
well-defined pharmacology. It belongs to a family of four
GPCRs (A1R, A2AR, A2BR, A3R) that mediate the actions of ade-
nosine and are attractive drug targets.25 The A2AR regulates the
release of the neurotransmitters dopamine and glutamate in
the brain, regulates blood flow to cardiac muscle and is the
target for the most widely used psychoactive drug – caffeine,
which blocks this receptor.26 In this study, utilising the
human A2AR as the GPCR, we demonstrate for the first time,
the application of FCS to provide quantitative data on the
binding characteristics of a GPCR that has been purified
embedded within the nanoscale bilayer of the SMALP. This
SMALP strategy ensures that the native lipid in close-associ-
ation with the receptor protein has never been disrupted by
detergent at any stage. Our study not only establishes the
utility of employing FCS for characterising GPCR-SMALPs, but
opens up the possibility of exploiting high-throughput solu-
tion-based FCS,27 and highlights the potential for identifying
novel fluorescent ligands targeted to specific GPCRs. In recent
years, SMA has been widely used to solubilise structurally-
diverse membrane proteins from a wide range of species
(including bacteria, yeast, plants, insect cells and mammalian
cells). The application of SMA for studying GPCRs and other
membrane proteins is increasing rapidly as the utility of
SMALPs becomes ever more apparent. Furthermore, ‘second-
generation’ SMA-like polymers have already been reported that
possess different properties to SMA, so the field is still
expanding.28–30 The application of FCS as a quantitative, real-
time technique, with single molecule sensitivity will have wide-
spread utility for the development of down-stream applications
of SMALPs as an investigation platform in this growing field.
Experimental
Materials
CA200645 was supplied by HelloBio (Bristol, UK). SMA2000
anhydride was from Cray Valley (UK). ZM241385 {4-(2-[7-
amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5yl amino]
ethyl)phenol} was purchased from Tocris.
Human A2AR expression
Human A2AR was expressed in Pichia pastoris as described pre-
viously.11 Prior to SMA-extraction, cells were disrupted follow-
ing suspension in breaking buffer (50 mM sodium-phosphate
buffer, 100 mM NaCl, 5% glycerol, EDTA-free protease inhibi-
tor, pH 7.5, 4 °C) by 3–5 passes using an Avestin-C3 cell-disrup-
ter. Unbroken cells and debris were removed by centrifugation
(5000g, 10 min, 4 °C). The A2AR-expressing membrane fraction
was then sedimented (100 000g, 60 min, 4 °C) and re-sus-
pended to 80 mg mL−1 (wet weight) in extraction buffer
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(300 mM NaCl, 20 mM HEPES, pH 7.5). Membranes were
stored at −80 °C until needed.
Generation of A2AR-SMALPs
SMA was prepared from SMA anhydride and used to solubilise
A2AR from membranes as described previously.
11,12 Briefly,
A2AR-expressing membrane preparations were thawed on ice,
and an equal volume of 2× SMA buffer (5% w/v SMA, 300 mM
NaCl, 20 mM HEPES, EDTA-free protease inhibitor, pH 7.5)
added to yield a final concentration of 40 mg mL−1 (wet
weight) in 2.5% (w/v) SMA. Following gentle agitation for 1 h
at room temperature, non-solubilised material was removed by
centrifugation (100 000g, 60 min, 4 °C) to yield a supernatant
containing A2AR-SMALPs.
Purification of A2AR-SMALPs
All purification steps were carried out at 4 °C. The A2AR-SMALP
supernatant was incubated with ∼1 mL Ni2+-NTA resin, over-
night on an end-over-end rotator. The column was washed
with 20 column volumes (cv) of wash buffer (300 mM NaCl,
20 mM HEPES, 25 mM imidazole, EDTA-free protease inhibitor
pH 7.5). Elution of A2AR-SMALP was achieved with 10 cv of
elution buffer (300 mM NaCl, 20 mM HEPES, 250 mM imid-
azole, EDTA-free protease inhibitor pH 7.5). Elution fractions
were pooled, buffer-exchanged into assay buffer (300 mM
NaCl, 20 mM HEPES, pH 7.5) and concentrated using spin-
concentrators (10 kDa cut-off ). Concentrations of purified
A2AR-SMALP were determined using SDS-PAGE and densio-
metric analysis against protein standards in ImageJ.31 Final
concentrations ranged between 0.2–1 mg mL−1.
FCS protocols
Solution-based FCS was performed essentially as described
previously.15 FCS measurements were carried out on Nunc
Lab-Tek 8-well chambered #1.0 cover-glasses (Thermo
Scientific, UK), using a ZEISS LSM510 Confocor3 using
633 nm excitation (0.5–1 kW cm−2), with emission collected
through an LP650 filter. The confocal volume was placed
200 μm above the surface of the coverslip. Cy5 NHS ester
(Amersham Pharmacia Bioscience) was prepared in high per-
formance liquid chromatography grade water (Chromasolv,
Sigma-Aldrich, UK). As Cy5 has a known diffusion coefficient
(D = 3.16 × 10−10 m2 s−1), it was employed as the standard fluo-
rescent dye (10 nM and 500 nM) to calculate the confocal
volume dimensions using eqn (1), where V = volume (mL), W1
is the radius of the confocal volume, determined from W1 =
(4·D·τD1)½, where D and τD1 are the diffusion coefficient and
dwell time of Cy5, respectively. W2 represents half the height
of the confocal volume and is calculated by multiplying W1 by
the structural parameter (S). Calibration readings were taken
on each day’s experiments. FCS measurements were performed
in a final assay volume of 200 μL. A2AR-SMALPs were incubated
with CA200645 (25 nM), in the presence or absence of varying
concentrations of ZM241385 as stated. Equilibrium was estab-
lished at 30 min and four read-times, each of 10 s, were
employed to record time-dependent fluctuations in fluorescent
intensity.
Data analysis
Autocorrelation analysis was performed using Zeiss AIM 4.2
software. Cy5 calibration data were used to calibrate the detec-
tion volume as previously described.15 Experimental data were
fitted to eqn (2), where N = particle number, fi is fraction of i
th
component, τDi is dwell time of i
th component, S = structure
parameter (ratio of diameter to height of volume). A 1-com-
ponent or 2-component 3-D diffusion model was used incor-
porating a triplet state component fitted using a pre-exponen-
tial. Fit quality was assessed on residuals to the fit. For 2-com-
ponent fits, the first component (τD1), representing free
ligand, was fixed during the fitting process to the value deter-
mined for CA200645 alone, and the second component (τD2)
represented bound ligand. The concentrations of free and
bound components were then calculated directly from their
relative contributions to the amplitude of the autocorrelation
function. Specific binding was determined using eqn (3). Total
binding was defined as N(τD2) (nM) as calculated from the
autocorrelation analysis curve for A2AR-SMALPs in the absence
of competing ligand. Non-specific binding was defined as
N(τD2) (nM) calculated from the autocorrelation analysis curve
for A2AR-SMALPs in the presence of saturating competing
ligand. The affinity (pKi) of ZM241385 binding to the
A2AR-SMALP was determined from the IC50 value of the
ZM241385 competition binding curve following correction for
occupancy by the tracer ligand CA200645.32 The Stokes–
Einstein equation (eqn (4)) was utilised to probe the relation-
ship between the diffusion time of the SMALP nanoparticle
and its’ hydrodynamic radius; where D = diffusion coefficient,
kB is Boltzmann’s constant, T = temperature (K), η = dynamic
viscosity and r = radius of the particle. Pooled data are pre-
sented as the mean ± s.e.m. for 3, or 4, independent prep-
arations of A2AR-SMALP. Significance (p < 0.05) was deter-
mined by Student’s paired t-test.
V ¼ π32  ð1Þ2 2 ð1Þ
GðτÞ ¼ 1þ 1
N

Xm
i¼1
fi  1þ τ
τDi
 1
 1þ τ
S2  τDi
 12
ð2Þ
Specific binding ¼ Total binding  Nonspecific binding ð3Þ
D ¼ kBT
6πηr
ð4Þ
Results and discussion
A2AR-SMALPs provides a platform for FCS
The A2AR-SMALPs were generated using SMA (2.5% w/v) to
extract the receptors from A2AR-expressing membranes into
SMALPs, followed by purification of the A2AR-SMALPs as pre-
viously described (Fig. S1†).11 The current studies utilized the
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2020 Nanoscale
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 1
9 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 5
/2
2/
20
20
 8
:3
1:
45
 A
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
fluorescent ligand CA200645, which comprises the adenosine
receptor antagonist xanthine amine congener (XAC) linked to a
red BODIPY630/650 fluorophore via a β-alanine linker.33
CA200645 is a high affinity ligand for both the A1R and A3R
subtypes33–35 and was used previously as the tracer ligand to
investigate dimerization and allostery of A3R in whole live cells
using FCS.20 Given that CA200645 is derived from the non-
selective adenosine receptor antagonist XAC, it was hypoth-
esized that CA200645 would not be A1R/A3R-selective and
would also bind to the A2AR. Subsequent pharmacological
characterization established that CA200645 bound to the A2AR
with high affinity (42 nM; pA2 = 7.37 ± 0.17, n = 3; Fig. S2†).
The initial stage of the investigation was to optimize the
concentration of CA200645 for solution-based FCS, to ensure
that specific binding to the A2AR encapsulated in the SMALP
was high compared to non-specific binding. The CA200645
concentration was varied between 5–300 nM and non-specific
binding determined in each case by adding a saturating con-
centration of a non-fluorescent competing A2AR ligand
(ZM241385,36 1 µM). Specific binding varied between 20 ± 11%
and 70 ± 12% of total binding (Fig. 1), with 25 nM CA200645
being used in all subsequent experiments. A data-collection
time of 10 s was routinely employed which provided ample
fluorescent fluctuation data for autocorrelation analysis.
The initial FCS experiments were performed with CA200645
alone in assay buffer to determine the characteristics of the
free ligand. Fluctuations in fluorescence intensity for
CA200645 over time are shown in Fig. 2a. Autocorrelation ana-
lysis of these fluctuations revealed a monophasic autocorrela-
tion curve (Fig. 2b) with an average dwell time (τD) of the fluo-
rescent moiety within the detection volume of 68 ± 2 μs and a
diffusion coefficient D = 287 ± 15 μm2 s−1, (mean ± s.e.m., n =
4) with residuals (Fig. 2c) confirming that there was no sys-
tematic deviation in the fitted curve. The experiments were
then repeated using CA200645 in the presence of A2AR-SMALP.
The fluorescence intensity fluctuations for CA200645 +
A2AR-SMALP are shown in Fig. 2d. Analysis of these fluctu-
ations revealed that the autocorrelation curve for CA200645
was significantly altered by the addition of A2AR-SMALP. In
contrast to the monophasic curve observed for ligand alone
(Fig. 2b), the autocorrelation curve for CA200645 +
A2AR-SMALP was clearly biphasic (Fig. 2e) exhibiting fast and
slow diffusing components (τD1 and τD2, respectively) with the
residuals (Fig. 2f) confirming that there was no systematic
deviation in the fitted curve. The faster diffusing component
exhibited a dwell-time (τD1) consistent with the free ligand
(Fig. 2b). The slower component had an average dwell-time
(τD2) for CA200645 of 625 ± 23 µs and a diffusion coefficient
D = 30 ± 4 μm2 s−1 (mean ± s.e.m., n = 4). As a control,
A2AR-SMALPs alone were shown to have no detectable auto-
fluorescence (Fig. S3†).
Characterization of the slower diffusing component (τD2)
The logical explanation for the emergence of the slower
diffusing component in the presence of A2AR-SMALP is that
the ligand was binding to the receptor in the A2AR-SMALP and
that both free and bound CA200645 were being detected by
FCS simultaneously as τD1 and τD2 respectively (Fig. 2e).
Indeed, the simultaneous determination of the free ligand
concentration precisely where the binding event is occurring is
a particular benefit of FCS for characterising ligand : GPCR
complexes. The binding of CA200645 to the A2AR-SMALP could
have been specific binding to the encapsulated GPCR or could
possibly have been non-specific binding caused by partitioning
of CA200645 into the lipid bilayer of the SMALP or interaction
of the ligand with the SMA polymer surrounding the SMALP.
The pharmacological properties of the receptor were exploited
to establish the nature of the binding. A competing A2AR-selec-
tive ligand ZM241385 was used at a saturating concentration.
This would fully occupy the available A2AR binding sites and
prevent binding of CA200645 but would not prevent any non-
specific binding. The τD2 component of the autocorrelation
curve for CA200645 + A2AR-SMALP in the absence, and pres-
ence, of ZM241385 (1 µM) is shown in Fig. 3. In the presence
of ZM241385, the τD2 component particle number (N)
decreased by 62%, as the ZM241385 competed for the ligand
binding site of the receptor and prevented CA200645 binding.
In contrast, there was no effect of ZM241385 (1 µM) in control
experiments performed using a different membrane protein
encapsulated in a SMALP (ZipA, derived from Escherichia coli).
ZipA-SMALP showed a lower particle number than
A2AR-SMALP consistent with low CA200645 binding expected
in the absence of receptor (Fig. 3).
A range of ZM241385 concentrations between 10−12 M–10−6
M was used to construct a competition curve for ZM241385
binding to the nano-encapsulated A2AR using FCS with
CA200645 as tracer ligand (Fig. 4). From these data, the affinity
(pKi) of ZM241385 for the A2AR-SMALP was calculated as 8.2 ±
0.5 (mean ± s.e.m., n = 3). This is not significantly different to
Fig. 1 Optimisation of tracer ligand concentration for solution-based
FCS with A2AR-SMALPs. The specific binding of CA200645 to A2AR
encapsulated in a SMALP was determined at the stated concentrations.
Non-specific binding was defined by a saturating concentration of
ZM241385 (1 µM). Data are mean ± s.e.m. (n = 3).
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the reported affinity of ZM241385 binding to A2AR in the orig-
inal membranes (pKi = 7.95 ± 0.45).
11
The diffusion coefficient of the CA200645:A2AR-SMALP
complex (D = 30 ± 4 μm2 s−1) was used to estimate the hydro-
dynamic radius of the A2AR-SMALP as calculated by the
Stokes–Einstein equation (eqn (4)), with the caveat that
SMALPs are disc-shaped rather than spherical. The resulting
values of 7–9 nm were consistent with the published values for
the SMALP diameter of c.10 nm determined by a wide range of
biophysical techniques, including small angle neutron scatter-
ing (SANS), electron microscopy (EM), attenuated total reflec-
tion Fourier transform infrared spectroscopy (ATR-FTIR),
differential scanning calorimetry (DSC) and nuclear magnetic
resonance spectroscopy (NMR).10,37
Numerous applications of FCS with GPCR-SMALPs can be
envisaged. For example, allosteric modulators of GPCRs bind
to sites on the receptor discrete from the ‘classical’ ligand
binding site and are of current interest to the pharmaceutical
industry as they have therapeutic potential for ‘tuning’ recep-
tor signalling (up or down).38 The size differential between
Fig. 2 FCS analysis of CA200645 binding to purified A2AR-SMALP. (a) Fluctuations in fluorescent intensity with CA200645 alone. (b) Autocorrelation
curve for CA200645 alone, fitted to a single-component diffusion model. (c) Deviation of data for CA200645 alone from the fitted curve. (d)
Fluctuations in fluorescent intensity with CA200645 + A2AR-SMALP. (e) Autocorrelation curve for CA200645 + A2AR-SMALP fitted to a two-com-
ponent diffusion model, in which the first component (τD1) was fixed to a three-dimensional diffusion rate of the free-ligand in solution. (f ) Deviation
of data for CA200645 + A2AR-SMALP from the fitted curve.
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GPCR-SMALPs and fluorescent ligands is sufficiently large that
FCS will be a useful tool in the future for investigating poten-
tial allosteric modulators as it is compatible with a very wide
range of modulator sizes from small molecules to therapeutic
antibodies. Of course other approaches for nano-encapsulation
of GPCRs, such as reconstituted lipid nanodiscs stabilised by
an annulus of membrane scaffolding proteins39 or the use of
recently-reported SMA-like polymers,28–30 may also be compati-
ble with characterisation using FCS.
The application of SMALPs to studying membrane proteins
is expanding rapidly40 and recently SMALPs have been used to
obtain high resolution structures of membrane proteins;
including crystallisation of the proton pump bacteriorhodop-
sin transferred from SMALPs into lipidic cubic phase for in
meso crystalisation13 and the cryo-EM structure of bacterial
alternative complex III in a super-complex with cytochrome
oxidase encapsulated in a SMALP.14 Combining the techno-
logies of fluorescence imaging and SMALP-solubilisation for
studying membrane proteins is becoming increasingly versa-
tile. For example, using proteins fluorescently labelled via
introduced unnatural amino acids to enable single-molecule
fluorescence studies and using FCS to confirm the existence of
dimers of the transporter protein ABCG2 and its interaction
with substrate.41,42 This expanding utility of SMALPs has been
the driver for developing new amphipathic co-polymers that
retain the ability of SMA to solubilise membrane proteins but
exhibit different physico-chemical characteristics to SMA. For
example, styrene-co-maleimide (SMI) is positively-charged and
retains functionality at acidic pH, in contrast to the negative
charge and alkaline working range of SMA;28 styrene male-
imide quarternary ammonium (SMA-QA) forms relatively large
nanodiscs (∼30 nm diameter) that remain stable between pH
2.5–pH 10;29 diisobutylene-co-maleic acid (DIBMA) in which
the styrene aromatic ring of SMA is replaced by the aliphatic
diisobutylene thereby changing how the polymer interacts
with the lipid in the nanoparticles30 and thiolated SMA
(SMA-SH) which can be derivatised or immobilised via the
introduced thiol.43 All of these ‘second generation’ polymers
generate lipid nanoparticles in the complete absence of deter-
gent so preserve the native lipid in close association with the
membrane protein. This is particularly important for GPCRs,
as it has been shown that they can be regulated by the juxtapo-
sition of specific membrane lipids. For example, phosphatidy-
lethanolamine and phosphatidylglycerol favour inactive and
active conformational states of the β2-adrenergic receptor (β2-
AR), respectively.44 Likewise, cholesterol can modulate receptor
conformation45 and function.46,47 Indeed a specific cholesterol
binding site incorporating a ‘cholesterol consensus motif’ has
been proposed for some GPCRs following the identification of
cholesterol in GPCR crystal structures.48 In addition, the
selectivity of the β1-AR for signalling via the G-protein Gs, in
preference to other G-proteins, is enhanced by the membrane
lipid phosphatidylinositol 4,5 bisphosphate (PIP2) but not by
structural homologues. Using engineered ‘mini-Gα’ constructs,
formation of β1-AR : mini-Gs complex was stabilised by two
molecules of PIP2 whereas PIP2 did not stabilise coupling
between β1-AR and other mini-Gα subunits.49 Although the
plasma membrane of P. pastoris differs from that of mamma-
lian cells, notably in substitution of cholesterol by ergosterol,
the major classes of phospholipids are similar and the A2AR
was pharmacologically active.50 Furthermore, phospholipids in
SMALPS can also be exchanged,51 which offers opportunities
in the future for modifying the lipid composition following
isolation of GPCRs in SMALPs. Overall, the preservation of
native lipid encapsulated in GPCR-SMALPs combined with the
Fig. 3 Specific binding of CA200645 to A2AR-SMALP detected with
FCS. The particle number of the (τD2) component of the autocorrelation
curve is shown for CA200645 (25 nM) binding to A2AR-SMALP or to
ZipA-SMALP, in the absence (−) or presence (+) of a saturating concen-
tration of competing ligand ZM241385 (1µM). **p < 0.01, NS = not sig-
nificant. Data are mean ± s.e.m. (n = 3).
Fig. 4 Competition binding curve derived using FCS with A2AR-SMALP.
CA200645 (25 nM) was used as fluorescent tracer ligand in FCS experi-
ments with A2AR-SMALP in the presence of ZM421385 at the concen-
trations indicated. Data are mean ± s.e.m. (n = 3).
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advantages of FCS described above, establishes a versatile plat-
form for investigating ligand : GPCR interactions specifically,
and membrane protein interactions in general, in the future.
Conclusions
Nanodisc technology is becoming widely adopted as a mem-
brane protein solubilisation strategy due to the benefits pro-
vided by SMALPs over other solubilisation approaches.
Proteins are directly solubilised from membranes with preser-
vation of the annular lipids thereby maintaining the native
environment of the encapsulated protein. This is a notable
advantage for research focusing on the large GPCR family of
membrane proteins which constitute the primary therapeutic
target for drug discovery.6
Nano-encapsulation of one of these GPCRs (the A2AR) into
SMALPs allowed us to report the first use of solution-based
FCS to investigate the ligand binding capability of the receptor
within the nanodisc particle in real time. Our study estab-
lished that GPCR-SMALP used in combination with FCS is a
powerful approach for characterising ligand : receptor com-
plexes in a nano-scale native environment. It is anticipated
that given the versatility and general utility of our strategy, it
can be applied to the quantitative investigation of a wide range
of target receptors plus their cognate ligands, modulators and
interacting protein partners in the future.
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